11.01.2023 11:00
Biotech startup STALICLA has acquired global rights for Novartis’ drug candidate, mavoglurant, a treatment for substance-use disorders and neurodevelopmental disorders (NDDs). The deal includes an undisclosed upfront fee, equity, and up to $270 million in development and commercial milestone payments.